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Abstract
The use of long hormonal contraceptives can disrupt the balance of estrogen in the body and resulting in abnormal cell changes. By using a case-control de-
sign, this study aimed to determine the association between duration of hormonal contraception use and the risk of cervical cancer. The study population was
composed of patients examined in 2018 at a cancer installation and obstetrics-gynecology polyclinic of the Central General Hospital in Yogyakarta. Random
sampling yielded 95 women diagnosed with cervical cancer assigned for the case group and other 95 women with negative pap smear results for the control
group. Data on the dependent variable (cervical cancer) and the independent variable (duration of hormonal contraception), based on the length of hormonal
contraceptive use, were both obtained from the medical records. Assessment of cervical cancer was based on the doctor’s diagnosis. Using logistic regression
for data analysis, results showed that 44.7% of samples used long-term hormonal contraceptives (over five years). Length of use of hormonal contraceptives
had a significant correlation with the incidence of cervical cancer (p-value < 0.01). Use of hormonal contraceptives for more than five years increased the risk
of cervical cancer by 4.2 times (95% CI 1.01–5.69) compared to less than five years of use after controlled by first marriage age and parity.
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Introduction
Cervical cancer is a leading cause of mortality in
women in the world, including Indonesia.1 This type of
cancer ranks third as the cause of mortality in women the
world over, with an estimated mortality rate of 15 per
100,000 women.2 While, in developing countries,
including Indonesia, cervical cancer ranks as the top most
common cause of death in women at about 80% of the
total cases.3 The number of cervical cancer patients in
Indonesia is estimated to be 90–100 per 100,000
inhabitants per year.4,5,6 Yogyakarta is the region with
the highest incidence of cancer in Indonesia, with the
prevalence of cervical cancer at 1.5%.7,8 Cervical cancer
consistently ranks third in the top ten major cancers
treated at the Dr. Sardjito Central General Hospital. 
Cervical cancer is a disease with a relatively long
development period. From the precancerous stage, it
takes 10 to 20 years to develop into invasive cancer.
Patients can complain of severe pain that can be felt
during sexual intercourse, accompanied by abnormal
bleeding. When cancer has spread to the brain and lungs
(pulmonary stage, IVB), the patient life will be
increasingly difficult to save.9,1 Study conducted in 2017
by Yvonne, et al., showed that of 821 women diagnosed
with cervical cancer, 497 (60.5%) died during follow up.
The chances of a cervical cancer patient to survive one
year after diagnosis is 62%; three years after diagnosis,
29%; and 5 years after diagnosis, 30%.10
Studies showed that several factors significantly
correlate with cervical cancer. These are early sexual
intercourse (engaged before 20 years), parity (more than
three live births), and the use of hormonal contraceptives
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(exceeding five years).1 The risk factors of this type of
cancer are low education; infections by Trichomonas
vaginalis, bacterial vaginosis, disorders on genitals; and
contraceptive use.11 The effect of exposure to different
hormones on the risk of developing cancer is not yet fully
understood. Duration of each hormonal contraceptive
usage still needs to be examined.12
The number of active family planning participants
from 2014 to 2016 showed an upward year-to-year trend.
The percentage of active family planning participants
who used hormonal contraceptives ranged from 81.58%
to 81.97% (injectables, 47.54%; pills, 23.58%;
implants, 10.46%).13 The aim of this study was to
determine relationship between duration of hormonal
contraceptive use and incidence of cervical cancer, and
to identify other factors related to cervical cancer
incidence. 
Method
This study used a case-control design that composed
of patients examined in 2018 at a cancer installation and
obstetrics-gynecology polyclinic in the Central General
Hospital in Yogyakarta. 95 women diagnosed with a
cervical cancer assigned for the case group, and the other
95 women with negative pap smear results for the control
group. Subjects were excluded if they had never used
hormonal contraceptives or if their medical record data
is incomplete. The independent variable was the duration
of hormonal contraceptive use, whereas the dependent
variable was cervical cancer, assessed by the doctor’s
diagnosis recorded in each subject’s medical record. The
duration of hormonal contraception refers to the length
of use of hormonal contraceptives (injectables, pills, and
implants). 
The duration of hormonal contraceptive use
(injectables, pills, and implants) was categorized into
two, more than five years and less than five years.
Possible confounders age of marriage below 20 years old,
family records of cancer, active smoking, and 3 parities
or higher. For statistical analysis, chi-square test was used
for bivariate analysis and the logistic regression was used
for multivariate analysis. The p-value of the likelihood
ratio to the chi-square was used as a guide to the subject’s
goodness of fit. All p-values were two-tailed and
statistical significance level was set as less than 0.05.
Ethical approval was granted for the study by the Ethics
Committee of the Faculty of Medicine, Gadjah Mada
University No.KE/KF/0561/EC/2018.
Results
The total number of subjects who participated in this
2018 study conducted at the Central General Hospital in
Yogyakarta was 190 subjects consisting of 95 women
diagnosed with cervical cancer as the case group and 95
women who did not have cervical cancer or had negative
pap smear tests as the control group. The duration of
hormonal contraceptive use (injectables, pills, and
implants) was categorized into long (“> 5 years” (more
than five years) and “not long” (less than five years).
Table 1 presents the correlation of the duration of use of
hormonal contraceptives with cervical cancer and other
affecting factors.
This study investigated the correlation between the
duration of use of hormonal contraceptives, the age of
first marriage, parity, active smoking, and family records
of cancer with cervical cancer. The use of hormonal
contraceptives for more than five years led to risk 4.3
times higher  of cervical cancer than if the use was less
than five years. Duration of  pills, injectables, and
implant use have a significant correlation with cervical
cancer. Women whose age at first marriage was < 20
years presented with a 2.3 times higher risk of cervical
cancer. Parity greater than 3 increased the risk of the
disease by 2.5 times. No significant correlation between
active smoking and family record of cancer with cervical
cancer were found.
Association between cervical cancer and the duration
of the use of hormonal contraceptives, the age of
marriage, parity, active smoking, and family records of
cancer was analyzed by logistic regression using the
Table 1. Association of the Duration of the Use of Hormonal Contraceptives, Age of Marriage, Parity, Active
              Smoking, Family Record of Cancer with Cervical Cancer 
Variable                                                      Case                Control            p-Value      OR            95% CI
                                                                   
                                                                   n (%)                 n (%)                                          Lower      Upper
Hormonal contraception > 5 years           59 (62.1)           26 (27.4)             0.01         4.3         2.35         8.02
Use of pills > 5 years                                16 (51.6)             3 (13.0)             0.01         7.1         1.74         28.9
Use of injections > 5 years                       32 (66.7)           13 (35.1)             0.01         3.6         1.49         9.11
Use of implants > 5 years                         11 (68.8)           10 (28.6)             0.01         5.5         1.51         19.9
Married age < 20 years old                      47 (49.5)           28 (29.5)             0.01         2.3         1.29         4.25
Parity > 3                                                 27 (28.4)           13 (13.7)             0.02         2.5         1.20         5.22
Active smoking                                            2 (2.1)               0 (0.0)             0.49         2.0         1.75         2.33
Family record of cancer                                2 (2.1)               2 (2.1)             1.00       1.00         0.13         7.24
Notes:
n = The number of sample; OR = Odds Ratio; CI = Confidence Interval
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Table 2. Association of Duration of the use of Hormonal Contraception and Cervical Cancer 
              after Consideration of External Variables
Variable                                                             β              p-Value        OR                95% CI
                                                                                                                              Lower     Upper
Use of contraception hormonal >5 years        1.435            0.000           4.2          1.011       5.692
The first age of married < 20 years                0.659            0.046           1.9          0.993       4.847
Parity > 3                                                      0.786            0.052           2.1          2.238       7.880
Notes: 
β = coefficient; OR = Odds Ratio; CI = Confidence Interval
backward method. The first step of regression analysis
was performed by bivariate selection. Only variables with
p-value < 0.250 were inputted for the multivariate
analysis. The analysis showed that the age of marriage
and parity had p-value < 0.250 while active smoking and
family records of cancer had p-value > 0.250, therefore
the two latter variables were not included in the
multivariable selection.
The results showed that the association between the
duration of the use of hormonal contraceptives and
cervical cancer after consideration of external variables
(age of married < 20 years and parity greater than 3) was
significant. The period of use more than 5 years of
hormonal contraceptives led to 4.2 times higher risk of
cervical cancer after controlled by the age of first
marriage and parity (Table 2).
Discussion
This study found an association between the duration
of the use of hormonal contraceptives and cervical can-
cer. This strong association was marked with odds ratio
(OR) of 4.2. The results of the present study are similar
with or supportive of previous studies showing that the
duration of the use of hormonal contraceptives was asso-
ciated with cervical cancer, including a study finding that
long-term use of hormonal contraceptives could lead to
cervical cancer. A biologically plausible mechanism for
this relationship is that hormonal contraceptives act as a
tool for controlling the growth of neoplasms. The accep-
tors who use hormonal contraceptives are often found in
cervical dysplasia.14 The use of hormonal contraceptives
for more than four or five years can disrupt the balance
of estrogen in the body, resulting in abnormal cell
changes. Estrogen is likely to be one of the factors that
can affect Human Papilloma Virus Deoxyribonucleid
Acid (HPV DNA) replication.4 The length of use of each
hormonal contraceptive is a factor. 
Hormonal contraceptives can cause hypersecretion
and the proliferation of endocervical glands. Besides,
their use cause metaplasia and portio epithelial dysplasia
and affects the mucous membranes of the endocervix.
Hormonal contraception increases the risk of cervical
cancer for women with HPV. It is suspected that gestagen
triggers the carcinogenic effect of HPV.7,14
The use of hormonal contraceptives enhances mucus
viscosity in the cervix, particularly oral contraceptives or
injectables, thus serving to increase the risk of cervical
cancer. This is because mucus viscosity tends to support
the presence of carcinogenic agents carried to the cervix
through sexual intercourse, including the HPV virus that
is the primary cause of cervical cancer. The duration of
implant contraceptives use can also increase the inci-
dence of cervical cancer, and the mechanism of this con-
traception method involves hormonal action to thicken
cervical mucus. The process of cervical mucus removal is
the replacement of new cells and the addition of cells to
the cervix to prevent the entry of sperm. If cervical mucus
thickening occurs continuously and uncontrollably, the
mucosal thickening will become abnormal, which can
lead to cervical cancer because the resulting changes in
the immature female body can damage cells in the
cervix.15
Other factors such as first age of marriage and parity
were statistically related to cervical cancer incidence.
Engaging in early sexual intercourse can damage cervical
epithelial tissues or the vagina cavity wall, making them
susceptible to cell abnormalities that often result in ab-
normal growth.1 Women who begin sexual intercourse
before 20 years old is more at risk of developing cancer
cervix because, in the early adult period, the process of
squamous cell metaplasia is substantially higher, thus in-
creasing the risk of atypical squamous transformation, a
condition that often develops into cervical intraepithelial
neoplasia (NIS).16 Results of this study also follow pre-
vious studies showing women who had first sexual inter-
course before 20 years old were 2.41 times more likely to
develop cervical cancer. The exposure of the uterus to
the HPV results in abnormal growth deviating into pre-
cancerous/cervical cancer.7 Married age can be associat-
ed with cervical cancer because the cervical epithelial tis-
sues of the genital device that is not yet fully mature are
susceptible to damage. When in a damaged state, the ep-
ithelial tissues of the cervix can worsen, which can lead
to cell abnormalities and resulting in abnormal growth.
This is especially the case if the sexual partner is already
infected with HPV virus that is rapid contracting.3
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Women with high parity are associated with the
 occurrence of cervical column epithelium during preg-
nancy. This incidence causes new dynamics of immature
metaplastic epithelium that can increase the risk of cell
transformation, particularly in the cervix where it can re-
sult in persistent HPV infection.17 Sylvia showed that the
reproductive organs of women with multiple pregnancies
are susceptible to injury, which in turn makes it easier
for the HPV to cause cancer. This is especially true for
multiple pregnancies with low birth spacing because
damage to the epithelial tissue develops into the growth
of abnormal cells that are potentially malignant. The
process of labor and birth often presents an infectious
virus with an opportunity to contaminate the reproduc-
tive organs in cases of poor vaginal hygiene conditions,
and the resulting infection can become malignant.18
According to the American Cancer Society, if a
woman has a mother or sister with cervical cancer, the
risk of developing the disease is higher compared to those
who do not have a family record of the disease. This is
because cervical cancer can be genetically transmissi-
ble.19 However, the results of the present study indicate
that women whose families had a record of cervical can-
cer did not influence their risk of developing the condi-
tion. This study differs from the study showing that fam-
ily record of cervical cancer increases the risk of develop-
ing the disease by 2.19 times.2 Respondents who have
had cancer in their families presented with 14.93 times
higher risk for cervical cancer. Especially in the nuclear
family (first), cervical cancer is a vulnerability that is in-
herited. However, it is unclear whether the risks relating
to a record of cervical cancer in the family is due to ge-
netic susceptibility or familial influence on environmental
lifestyle.3 At present, there is a need for counseling on
contraceptive use, especially hormonal contraceptives,
because high levels of hormonal contraceptive use by ac-
ceptors are thought to be the effect of failure to provide
extensive information about the advantages and disad-
vantages of contraception and contraceptive services.20
The strength of this study is that the researchers con-
ducted a long-term study of hormonal contraceptive use
covering all types of contraception methods, such as pills,
injectables, and implants. External variables that affect
the incidence of cervical cancer such as the age at first
marriage, family record of cancer, active smoking, and
parities were analyzed in this study. The limitation of this
study is that data sources of hormonal contraceptive use
and cervical cancer were taken only from medical record.
The use of medical records can cause a non-differential
misclassification bias that can affect the accuracy of the
disease (cervical cancer) and exposure (duration of hor-
monal contraception) data. To ensure the accuracy of the
data, the researchers had anticipated this bias by selecting
a place of study, which is the Dr. Sardjito Central General
Hospital that has a complete medical record and where
all diagnoses are written by the obstetrician.
Conclusion
Duration of the use of hormonal contraceptives more
than five years has a strong association with cervical
cancer. Hormonal contraceptive use for more than five
years increases the risk for cervical cancer by 4.2 times
compared to the use of hormonal contraceptives for less
than five years. Other factors such as first marriage <20
years and parity were also contributed to cervical cancer
incidence, while smoking and family records were not
contributed to the incidence of cervical cancer.
Recommendation
For all women who do not want more children should
use non-hormonal long-term contraception. It is
necessary to disclose to women or contraceptive
acceptors using hormonal for up to five years.
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